About VolitionRX Ltd (NYSEMKT:VNRX)
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Diagnostic & Testing Substances
- Sub-Industry: N/A
- Symbol: NYSEMKT:VNRX
- CUSIP: N/A
- Web: www.volitionrx.com/
- Market Cap: $63.11 million
- Outstanding Shares: 26,518,000
- 50 Day Moving Avg: $2.70
- 200 Day Moving Avg: $3.20
- 52 Week Range: $2.28 - $5.45
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.18
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.63 per share
- Price / Book: 3.78
- EBITDA: ($13,230,000.00)
- Return on Equity: -79.20%
- Return on Assets: -63.86%
- Average Volume: 37,823 shs.
- Beta: -1.58
- Short Ratio: 3.43
Frequently Asked Questions for VolitionRX Ltd (NYSEMKT:VNRX)
What is VolitionRX Ltd's stock symbol?
VolitionRX Ltd trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "VNRX."
How were VolitionRX Ltd's earnings last quarter?
VolitionRX Ltd (NYSEMKT:VNRX) announced its quarterly earnings results on Thursday, May, 11th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. View VolitionRX Ltd's Earnings History.
When will VolitionRX Ltd make its next earnings announcement?
Where is VolitionRX Ltd's stock going? Where will VolitionRX Ltd's stock price be in 2017?
1 equities research analysts have issued 12-month target prices for VolitionRX Ltd's shares. Their predictions range from $10.00 to $10.00. On average, they expect VolitionRX Ltd's stock price to reach $10.00 in the next twelve months. View Analyst Ratings for VolitionRX Ltd.
Who are some of VolitionRX Ltd's key competitors?
Some companies that are related to VolitionRX Ltd include MaxCyte (MXCT), Arch Therapeutics (ARTH), Ekf Diagnostics Holding PLC (EKF), Synthetic Biologics (SYN), Matinas BioPharma Holdings (MTNB), Summit Therapeutics PLC (SUMM), Nobilis Health Corp (HLTH), Bovie Medical (BVX), Motif Bio PLC (MTFB), Immunodiagnostic Systems Holdings PLC (IDH), Ampio Pharmaceuticals (AMPE), Ergomed PLC (ERGO), Five Star Senior Living (FVE), Tissue Regenix Group PLC (TRX), Diurnal Group PLC (DNL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY) and Navidea Biopharmaceuticals (NAVB).
Who are VolitionRX Ltd's key executives?
VolitionRX Ltd's management team includes the folowing people:
- Martin Charles Faulkes, Executive Chairman of the Board
- Cameron John Reynolds, President, Chief Executive Officer, Director
- David Vanston, Chief Financial Officer, Treasurer
- Louise Dayas, Chief Marketing and Communications Officer
- Jason Bradley Terrell, Chief Medical Officer and Head of US Operations
- Rodney Gerard Rootsaert, Secretary
- Alan Colman, Director
- Edward W. Futcher Ph.D., Independent Director
- Guy Archibald Innes, Independent Director
- Habib Skaff, Independent Director
How do I buy VolitionRX Ltd stock?
Shares of VolitionRX Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VolitionRX Ltd's stock price today?
MarketBeat Community Rating for VolitionRX Ltd (NYSEMKT VNRX)MarketBeat's community ratings are surveys of what our community members think about VolitionRX Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of VolitionRX Ltd stock can currently be purchased for approximately $2.38.
Consensus Ratings for VolitionRX Ltd (NYSEMKT:VNRX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.00|Consensus Price Target History for VolitionRX Ltd (NYSEMKT:VNRX)
Analysts' Ratings History for VolitionRX Ltd (NYSEMKT:VNRX)
(Data available from 10/19/2015 forward)
|9/20/2017||HC Wainwright||Reiterated Rating||Buy||$10.00|
|9/7/2016||Rodman & Renshaw||Lower Price Target||Buy||$12.00 -> $10.00|
Earnings History for VolitionRX Ltd (NYSEMKT:VNRX)Earnings History by Quarter for VolitionRX Ltd (NYSEMKT VNRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|11/6/2014||($0.09)||($0.13)||$0.13 million||$0.02 million||View||N/A|
Earnings Estimates for VolitionRX Ltd (NYSEMKT:VNRX)
Current Year EPS Consensus Estimate: $-0.55 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS
Dividend History for VolitionRX Ltd (NYSEMKT:VNRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for VolitionRX Ltd (NYSEMKT:VNRX)Insider Trades by Quarter for VolitionRX Ltd (NYSEMKT:VNRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/19/2017||David Cecil Vanston||Insider||Buy||2,750||$2.84||$7,810.00|| |
|8/16/2017||Cameron John Reynolds||Insider||Buy||3,630||$2.77||$10,055.10|| |
|10/5/2016||David Matthew Kratochvil||CFO||Buy||10,000||$5.00||$50,000.00|| |
|5/20/2016||Cameron John Reynolds||CEO||Sell||3,390||$3.54||$12,000.60|| |
|5/15/2015||Cameron John Reynolds||CEO||Buy||1,500||$3.33||$4,995.00|| |
|2/11/2015||Guy Archibald Innes||Director||Buy||50,000||$3.75||$187,500.00|| |
|9/15/2014||Martin Charles Faulkes||Director||Buy||5,000||$2.16||$10,800.00|| |
|9/3/2014||Rodney Gerard Rootsaert||Insider||Sell||28,000||$1.80||$50,400.00|| |
Headline Trends for VolitionRX Ltd (NYSEMKT:VNRX)
Latest Headlines for VolitionRX Ltd (NYSEMKT:VNRX)
|VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding|
finance.yahoo.com - September 23 at 10:51 AM
|VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits|
finance.yahoo.com - September 23 at 10:51 AM
|HC Wainwright Reaffirms Buy Rating for VolitionRX Ltd (VNRX)|
www.americanbankingnews.com - September 20 at 5:10 PM
|VolitionRx Announces its European Colorectal Cancer Strategy|
finance.yahoo.com - September 19 at 8:25 PM
|Volition Granted Four Additional Patents|
finance.yahoo.com - September 15 at 11:04 AM
|VolitionRx to Attend Two Major Conferences in Asia|
finance.yahoo.com - September 15 at 11:03 AM
|VolitionRx Limited to Attend Multiple Conferences in September|
finance.yahoo.com - September 7 at 10:56 AM
|VNRX: Pathway Design Study Progressing. Expect European Launch in 2018|
finance.yahoo.com - August 30 at 3:47 PM
|Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers|
finance.yahoo.com - August 23 at 1:38 PM
|Cameron John Reynolds Purchases 3,630 Shares of VolitionRX Ltd (VNRX) Stock|
www.americanbankingnews.com - August 17 at 9:16 PM
|VolitionRX Ltd (VNRX) PT Set at $10.00 by HC Wainwright|
www.americanbankingnews.com - August 13 at 3:32 PM
|VolitionRX reports 2Q loss|
finance.yahoo.com - August 10 at 3:38 PM
|VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update|
finance.yahoo.com - August 10 at 9:29 AM
|VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update|
finance.yahoo.com - August 4 at 9:45 AM
|VolitionRX Ltd (VNRX) Set to Announce Quarterly Earnings on Thursday|
www.americanbankingnews.com - August 3 at 7:10 AM
|VolitionRX Ltd (VNRX) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - July 21 at 7:50 AM
|VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute|
finance.yahoo.com - July 19 at 9:11 PM
|Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute|
finance.yahoo.com - July 18 at 9:46 AM
|Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress|
finance.yahoo.com - July 1 at 8:52 AM
|Volition America, Inc. Retains Strategic Expert in Securing Non-Dilutive Funding Opportunities in the United States|
us.rd.yahoo.com - March 28 at 10:42 PM
|VolitionRx Limited Announces Full Fiscal Year 2016 Financial Results and Business Update|
us.rd.yahoo.com - March 10 at 9:35 AM
|Q4 2016 VolitionRX Ltd Earnings Release - Before Market Open|
us.rd.yahoo.com - March 10 at 9:35 AM
|VolitionRX reports 4Q loss|
www.cnbc.com - March 10 at 9:33 AM
|VolitionRx Limited's Triage Test Results Validated in Prospective Trial|
us.rd.yahoo.com - February 25 at 8:05 PM
|VolitionRx Limited's Novel Cancer Diagnostic Test Achieves CE Marking as it Prepares for Launch Across Europe|
us.rd.yahoo.com - January 4 at 7:38 AM
|9:03 am VolitionRx achieved CE marking on its Nu.Q Colorectal Cancer Screening Triage Test on December 28, 2016 as it prepares to launch across Europe|
us.rd.yahoo.com - January 4 at 7:38 AM
|Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee|
www.prnewswire.com - October 17 at 7:52 PM
|Volitionrx Limited (VNRX) Announces Presentation of Positive Blood Test for Colorectal Cancer Data|
www.streetinsider.com - October 12 at 12:56 PM
|VOLITIONRX LTD Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Mat|
biz.yahoo.com - October 11 at 7:46 PM
|VolitionRx Limited Announces Pricing of Public Offering of Common Stock|
www.prnewswire.com - October 1 at 8:45 AM
VolitionRX Ltd (VNRX) Chart for Thursday, October, 19, 2017